Lexicon Sotagliflozin and Pilavapadin Posters at ADA 2026: Type 1 Diabetes Subgroup Consistency and Phase 1 Renal-Function PK
Lexicon Pharmaceuticals presented two Sunday June 7 posters at ADA 2026. The pooled inTandem analysis of sotagliflozin, a dual SGLT-1/SGLT-2 inhibitor, showed consistent glycemic improvement and HbA1c reductions across key adult type 1 diabetes subgroups (M. Belinda Hardin). A separate Phase 1 study of the non-opioid pain candidate pilavapadin showed renal function did not affect its pharmacokinetics in patients with diabetic peripheral neuropathic pain (Rodica Pop-Busui).